National Institutes of Health to Grant Exclusive License for Antibody-Drug Conjugates for Cancer Treatment

Summary

The National Institutes of Health is considering granting an exclusive license to Oncolinx, Inc. to practice inventions related to Azonafide-derived compounds for the treatment of human cancers, as outlined in U.S. Patent No. 8,008,316.